Castle Biosciences Inc (NASDAQ:CSTL) closed its 2025 fiscal year with a fourth-quarter earnings report that delivered a significant top-line beat against analyst expectations, though profitability metrics presented a more complex picture. The market's initial reaction appears muted, reflecting a balance between the strong revenue performance and ongoing investments that pressured the bottom line.
Earnings and Revenue Versus Estimates
The company's fourth-quarter results surpassed Wall Street's revenue forecasts, while its adjusted loss per share was notably narrower than anticipated.
- Revenue: Reported Q4 revenue was $87.0 million, exceeding the analyst consensus estimate of approximately $80.6 million.
- Earnings Per Share: The company reported an adjusted net loss per share of $0.08 for the quarter. This figure was substantially better than the estimated loss of $0.29 per share that analysts had projected.
For the full year 2025, Castle Biosciences reported total revenue of $344.2 million, which exceeded the company's own previously issued guidance. This performance was achieved despite headwinds from a change in Medicare coverage for one of its tests and the discontinuation of another product.
Market Reaction and Price Action
Following the earnings release, the immediate market reaction has been neutral in after-hours trading. This subdued response suggests investors are weighing the positive revenue surprise against the company's current profitability challenges and its outlook for the coming year. Over recent weeks, the stock has faced pressure, declining approximately 19% over the past month, which may have priced in some concerns ahead of the report.
Key Elements from the Earnings Release
The earnings report highlighted several critical dynamics within Castle's business:
- Core Growth Engine: The company's foundational products, DecisionDx-Melanoma and TissueCypher for Barrett’s Esophagus, demonstrated robust momentum. Combined test report volume for these "core revenue drivers" surged 37% for the full year and 42% in the fourth quarter compared to the prior year periods.
- Portfolio Transition: Revenue growth was impacted by strategic decisions, including the discontinuation of the IDgenetix test in May 2025 and a refocus of commercial efforts for the DecisionDx-SCC test following a Medicare coverage change. Excluding these two products, revenue growth was 34% for the full year and 43% for the fourth quarter.
- Profitability Pressures: The company swung to a net loss of $24.2 million for the full year 2025, compared to net income of $18.2 million in 2024. This was attributed to increased operating expenses, including a significant one-time amortization charge, and continued investment in commercial expansion and research and development. Adjusted EBITDA for the year was $44.0 million, down from $75.0 million in 2024.
- Strong Balance Sheet: Castle ended the year with a solid financial position, holding $299.5 million in cash, cash equivalents, and marketable investment securities.
Forward Outlook and Analyst Comparisons
Management provided revenue guidance for 2026, anticipating total revenue between $340 million and $350 million. This forecast sits slightly above the current analyst consensus sales estimate of approximately $338.3 million for the full year 2026, indicating the company's confidence in maintaining its revenue base amid its portfolio transition.
The company also highlighted several recent clinical and commercial accomplishments, including the limited commercial launch of its new AdvanceAD-Tx test for atopic dermatitis and new peer-reviewed publications supporting the clinical utility of its flagship tests.
For a detailed breakdown of future quarterly estimates and historical earnings performance, readers can review more information on the Castle Biosciences earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.